Hang Yuan

Xi'an Jiaotong University First Affiliated Hospital

H指数:16

被引数:847

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mechanistic evidence for dibutyl phthalate as an environmental trigger for inflammatory bowel disease

iScience

IF4.1

2026-01-050

OAAI

Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study

DEB-TACE联合经动脉TQB2450灌注和口服安罗替尼作为晚期肝细胞癌一线治疗的疗效与安全性：一项单臂II期研究

Frontiers in Immunology

IF5.9

2025-09-010

DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation

TRIM28介导的DDX39B K63-linked泛素化通过增强ECAD溶酶体降解促进NSCLC转移

Signal Transduction and Targeted Therapy

IF52.7

2025-07-160

OAAI

Alkannin triggered apoptosis and ferroptosis in gastric cancer by suppressing lipid metabolism mediated by the c-Fos/SREBF1 axis

阿尔坎宁通过抑制由c-Fos/SREBF1轴介导的脂质代谢，在胃癌中诱导了凋亡和铁死亡。

PHYTOMEDICINE

IF8.3

2025-05-010

PRE

Oxidative Stress and Reprogramming of Lipid Metabolism in Cancers

氧化应激与肿瘤脂质代谢的重编程

ANTIOXIDANTS

IF6.6

2025-02-100

OAAI

Periodontal ligament fibroblasts utilize isoprenoid intermediate farnesyl diphosphate for maintaining osteo/ cementogenic differentiation abilities

JOURNAL OF DENTAL SCIENCES

IF3.1

2025-01-010

OAAI

Deubiquitinase JOSD2 alleviates colitis by inhibiting inflammation via deubiquitination of IMPDH2 in macrophages

去泛素化酶JOSD2通过巨噬细胞中IMPDH2的去泛素化来抑制炎症，从而缓解结肠炎。

ACTA PHARMACEUTICA SINICA B

IF14.6

2024-12-010

OAAI

N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis (vol 10, pg 554, 2023)

GENES & DISEASES

IF9.4

2024-11-010

OAAI

DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma

DDX39B通过促进肝细胞癌中GPX4前mRNA的剪接和胞质输出来保护索拉非尼诱导的铁死亡

BIOCHEMICAL PHARMACOLOGY

IF5.6

2024-07-014

PRE

Procyanidin B2 enhances anti-inflammatory responses of periodontal ligament cells by inhibiting the dominant negative pro-inflammatory isoforms of peroxisome proliferator-activated receptor g

JOURNAL OF DENTAL SCIENCES

IF3.1

2024-07-013

OAAI

Ultrasensitive detection of circulating tumor cells in clinical blood samples by a three-dimensional network nanovehicle-based aptasensor platform

SENSORS AND ACTUATORS B-CHEMICAL

IF7.7

2024-04-017

PRE

EEPD1 is identified as a predictor of prognosis and immune microenvironment through pan-cancer analysis and related to progression of colorectal cancer

HELIYON

IF3.6

2024-04-010

OAAI

Public RNA-seq data-based identification and functional analyses reveal that MXRA5 retains proliferative and migratory abilities of dental pulp stem cells

SCIENTIFIC REPORTS

IF3.9

2023-09-204

OAAI

Cytotoxicity, endocrine disrupting activity, and chemical analysis of 42 food contact silicone rubber products

SCIENCE OF THE TOTAL ENVIRONMENT

IF8

2023-05-0112

PRE

DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis

CELLULAR ONCOLOGY

IF4.8

2023-04-1314

ZNF32 prevents the activation of cancer-associated fibroblasts through negative regulation of TGFB1 transcription in breast cancer

ZNF32通过负调控TGFB1转录阻止乳腺癌中癌症相关成纤维细胞的激活

FASEB JOURNAL

IF4.2

2023-03-1911

PRE

Loss of exosomal miR-200b-3p from hypoxia cancer-associated fibroblasts promotes tumorigenesis and reduces sensitivity to 5-Flourouracil in colorectal cancer via upregulation of ZEB1 and E2F3

CANCER GENE THERAPY

IF5

2023-03-087

PRE

N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis

N6-methyladenosine修饰LINC00901通过IGF2BP2/MYC轴促进胰腺癌进展

GENES & DISEASES

IF9.4

2023-03-016

OAAI

DDX17 induces epithelial-mesenchymal transition and metastasis through the miR-149-3p/CYBRD1 pathway in colorectal cancer

CELL DEATH & DISEASE

IF9.6

2023-01-0218

OAAI

Loss of exosomal micro-RNA-200b-3p from hypoxia cancer-associated fibroblasts reduces sensitivity to 5-flourouracil in colorectal cancer through targeting high-mobility group box 3

FRONTIERS IN ONCOLOGY

IF3.3

2022-10-0511

OAAI

Hang Yuan

个人简介

教育背景

工作经历

荣誉奖项

研究方向